|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 19, 2019 ) According to the new market research “Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period.
The global Cell Surface Markers market is segmented based on product, source, cell type, application, end user and regions.
On the basis of antibodies by source, the global cell surface markers industry is segmented into mice, rats, and other sources. In 2018, the mice segment is expected to account for the largest share of the cell surface markers market. This segment is also expected to grow at the highest CAGR during the forecast period primarily due to the cost-effectiveness offered by mice models as a source of antibody production.
Download a PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216278622
Browse and in-depth TOC on in “Cell Surface Markers Market "
91 - Tables
40 - Figures
140 - Pages
The cell surface markers market, by cell type, is segmented into T cell surface markers, B cell surface markers, NK cell surface markers, monocyte cell surface markers, and other cell types. In 2018, the T cell surface markers segment is expected to account for the largest share of the cell surface markers market. The increasing use of these cell surface markers in research and diagnostics is expected to fuel the growth of this segment.
Based on application, the cell surface markers market is segmented into research and clinical applications. In 2018, the research applications segment is expected to account for the largest share of the cell surface markers market. The large share of this segment can primarily be attributed to the rising public-private funding for cell surface marker-based research and the growing use of cell surface markers in cancer, stem cell, and HIV research.
On the basis of end user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. The hospitals & clinical testing laboratories segment is expected to register the highest CAGR during the forecast period. The increasing incidence of chronic diseases such as cancer and HIV is expected to boost the demand for cell surface markers in hospitals & clinical testing laboratories in the coming years.
Request Free Sample Report @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=216278622
Market growth in North America, the largest regional market for cell surface markers, is primarily driven by the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.
Market Players
The key players in the Cell Surface Markers market are Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US).
View Complete Press Release @
https://www.marketsandmarkets.com/PressReleases/cell-surface-markers.asp
MarketsandMarkets™
Mr. Shelly Singh
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
